Enophthalmos eaused by inadequate maxillary sinusfu nction was first reported in 1964. Since this initial report, seattered ease reports and, more recently, reviews have appeared in the literature detailing the pathoph ysio logy, eliniea l findings, and management of this process. We present a elassie ease ofthe asymptomatic development of enophthalmos caused by maxillary sinus hypoventilation: the silent sinus syndrome. In addition, this ease included findings in the ethmo id sinuses that suggested their contribution to this disorder, which by our review of the literatu re has not been well deseribed.
Introduction
Prolonged hypoventilation of the maxillary sinus ca n result in atelectas is. The sile nt sinus syndrome is an example of this phenomenon, characterized by an absence of sym ptoms and the development of enophthalmos. Because the signs of this syndrome relate primarily to the eye, the diagnosis is typically made by our ophthalmology colleag ues . Nevertheless, the oto laryngologist should be aware of this condition and be prepared to assis t in its managemen t. In this article, we describe a case of silent sinus syndro me, and we discuss its management and rev iew the literature.
Case report
An otherwise healthy 49-year-old man sought the consultation of an ophthalmologist for an asymptomatic "si nking in" of his left eye over a 2-month perio d. Ophthalmologic examination revealed a prom inent left super ior palpebr al suleus, 2 mm of inferior globe displacement (hypoglobus), and 3 mm of enophthalmos as compared with his co ntralateral eye . Extraocular motility was intact. Evaluation includ ed comp uted tomograph y (CT) of the orbits, which demonstrated an increased left orbital volume and left maxillary, ethmoid, and fro ntal sinusitis . Referral was made to the otolaryngo logis t for management of chro nic sinusit is prior to the placement of an orbital floor implant.
Upon review, the patient spec ifically denie d any history of facial trauma, sinonasal or visual symptoms, or sinus surgery. Review of the CT scans revealed a partially opacified, atelecta tic left maxillary sin us with cen tripetal retraction of the med ial, postero latera l, and superior (orbital floor) walls of the sinus (figure I). The medial orbital floor and uncin ate process were dem ineralized. The uncinate process was laterally bowed and indistinguishable from the lateral nasal wall. The osteomeatal com plex was obstructed. On axia l view, there was focal inward bowing of the posterolatera l wall of the sinus , with widening of the pterygopalatine fossa and infratemporal fat plane (figure 2). The ipsi latera l middle turbin ate was vestigial in nature and retracted onto the lamina papyracea, and it occl uded the frontal recess . Hypop lasia of the anter ior ethmoid air cells was noted.
The patient underwent a left endosco pic uncine ctomy , maxillary antros tomy , and partial ethmoidectomy. Although he expe rienced a prompt reso lution of the enop hthalmos, the postoperative course was complicated by the development of sym ptomatic left frontal sinusitis, which was unrespo nsive to medical therapy. CT at this point revealed a pate nt left maxillary antrostomy, aeration of the previously affected sinus, and a retum of the posterior and superior sinus wall periosteum to their normal positions (figure 3). A subseq uent procedu re was performed, which included an endosco pic parti al middle turbinectomy and a frontal sinusotomy with ste nt placement. The stent was removed 4 weeks later. The patient retumed to cos metic base line 6 months postoperatively, and he remains symptom free .
Discussion
Proper paranasal sinus function requires ventilation, appropriate mucus production, and mucoci liary clearance. Ob struction of maxill ar y sinus ve nti la tion at the osteomeata l complex is accepted as a pathologic precur- The Irequeney and magnitude 01 laboratory abnormalit ies were similar in lexolenadine hvdroehlorideand placebo-treated patlents. Pedlalrie. Table 2 Iisls adverse experi enees in pati ents aged 6 to 11years 01 agewhich were reportedby grealer than2% of patients Ireatedwith lexolenadine hvdroehloride tablets at a dose 0130 mg twice dail y in plaeebo-eontrolled seasonal allergie rhinilis studiesin the UniledSlates andCanada Ihat were more common wilh lexolenadinehydroehloride than plaeebo. 6aek Pain Sinusitis Dizziness [jrowsiness OVEROOSAGE Rep erisof fexafenadinehydrochler ideoverdosehavebeeninfrequent andcontainlimitedinf errnatian.However, dizziness. drowsiness, anddry moulh have beenreported. Si ngle doses 01lexolenadine hydroehl oride up to 800mg(six normal volunteers at Ihis doselevel), and doses up10690 mg~' I i ee dailv lor 1 month (three normal volunteersat Ihis dose level)or 240mg onee dailv lor 1 year (234 normal volunteers at Ihis dose level) Vlere adminisleredwithout Ihedevelopmentof elinieallvsignilieant adverseevents aseomparedto plaeebo. In the event of overdase, consider standard measures to remave any unabsorbeddrug. Symptomatic and supporlivetreatmentis recammen ded. Hemodialysis did not eHeelivelv remove lexofenadine hvdroehlor ide Irom blood (1.7% removed) lollowing terfenadineadmi nistration. No deaths oeeurred at oral doses 01 lexofenadine hvdroehloride up to 5000mglkg in miee (110 times the maximum reeommended dai ly oral dosein adults and200times themaximumreeommended dailv oral dose in ehildren based onmg/m 2) andupto 5000mglkg in rats(230times Ihemaximum reeommended dailyoral dose in adults and400times the maximum reeommend eddail v oral dosein ehildren basedonmg/m 2) . Add itionallv, no elinieal signs 01 toxieily or gross pathol ogieallindingsVlere observed. in dogs, no evidenee 01toxieily Vl as observ ed al orai doses up to 2000mglkg (300times Ihemaximumreeommendeddailv oral dosein adults and 530limes themaximum reeommended dailv oral dose in ehildrenbasedon mg/m 2) . Preseribing Inlormati on as01 February 2000 Aventis Pharmaceuticals Inc.~~~~l t i~~~2 sJ4~3 1 0a s~ou ss el , Inc.) USPatenls 4,254,129; 5,375,693; 5,578,610 allb0200a ehronie IdioDathic Urtiearia Adverse events reported by patients 12years 01age and older in plaeebo-eontrolledehronie idiopathie urtiear ia sludies Vlere similar10 Ihose reported in plaeebo-eontrolled seasonal allergie rhinilis sludies. In plaeeboeonl rolled ehronie idiopalhie urtiearia elini eal Irials, Vl hieh ineluded 726 patients 12 vears 01 age and older reeei ving lexolenadinehydroehloride lablels at doses 01 20 10 240mg tVl iee dail y, adverseevenls Vl ere similar in lexolenadinehydroeh ioride and plaeebo-trealedpat ienl s. Table 3 Iists adverse experienees in patients aged 12vearsand olderVl hieh were reportedby great er than 2% 01palienl s Irealedwith lexolenadine hvdroehloride 60 mg lablets Iwiee dail y in e"ntrolled elinieal studies in the United Slates and Canada and that were more common wilh fexolenadine hvdroehloride thanplaeebo. The safely 01 lexof enadine hydroehloride in the treat· menl of ehronie idiopathie urtiearia in pedialriepati enls 6 to 11 Vears 01 age Is based on the safely prolil e 01 lexofenadinehvdroehl oridein adults andadoleseenl palientsat doses equal 10or higher thanIhereeommended dose (see PediatrieUse). lunet ion, eare should betakenin dose seleelion, and may beuselul to moni lor renal tunction. (See CUNICAL PHARMACOLOGY).
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AOVERSE REACTlONS
Seasonal Alla raie Rhinilis Adulfs, In plaeebo-eontrolled seasonal allergie rhinilis ennleal trialsin patients 12 years of ageand older,whieh ineluded 2461 pat ients reeeivinglexolenad inehydroehlorideeapsules at doses 01 20 mgto 240mgIVi icedaily, adverse events were similarinfexofenadine hydrochlonde and placebo-Ireatedpatients. All adverse events that were reportec by greater than 1% of patients wha received the recommended daily dose of fexofenadine hydroehloride(60 mgeapsules twicedaily), and thatwere morecommon with lexolenadinehydroehlorideIhan plaeebo, arelisled in Table 1 . In a placebo-controlled elinieal study in Ihe Uni tedStates. which ineluded570patlents aged 12 years ando lder reeeivinglexofenadine hvdroehloridetablets al doses 01120 or 180 mgoneedaily, adverseeventsweresimilar in lexofenadine hydroehloride and plaeebo-treat edpalients. Table 1 atso Iists adverseexperienees thatwere reportad by greater than 2% 01 palients treatedwith lexofenadine hydroehloride tabl etsal doses of 180 mgonee dailv andthatwere morecommon wil h fexofenad inẽ~~r~~~i l g~d c e e t~n~~~; sbeO ' e ven t s , including drowsiness, was not eese-retaec and was similar across subgroups defined by age, gender, and race. 
Coneomil anl Orug
Erythromyein (500 mgevery8 hrs) Ketoeonazole (400 mgoneedailv) Theehanges in plasmalevels were wilhin the range 01 plasma levet s aehieved in adequateand Vl ell·eonlrolled elini eal trials. The mechanism ofthese int eract ions has beenevaluated inin vi lto, in si lu, and in vivo ani mal modeIs. These studies indicate that ketoconazol e oreryt hromycin co·admini stration enhances fexofena· dine gasl rointestinal absorption. In vivo anim al studies also suggest that in addition to increasi ng abso rption, ketoconazole decreases lexofenad ine hydroehloride gaslrointestinal seerelion, while erythromycin may also decreasebili aryexcretion. In rai lertilily studies, dose-related reduetions in implanls and increases in postimplantation losses were observed at anoral dose 01 150 mglkg01lerlenadine (whieh led10lexofenadinehydroehloride exposures Ihat we re approximately 3 times the exposure of the maximum recommended daily aral dose of fexofenadine hydroehloride in adulls). Pregnancy Teralogenie Elleels: Calegorv C. There was no evidenee 01teratogenieily in rats or rabbits alorai doses 01 lerlenadine up 10300 mg/kg (Vlhieh led 10fexolenadi ne exposuresthal were approximatelV4 and 31 limes, respeelivelv, theexposurel rom themaximum reeommended dailvoraldoseof lexolenadine in adults). There are no adequat e and Vlell eontrolled studiesin pregnant women. Fexolenadine should be used during pregnanev onlyil the polential benelil jusliliesIhe polenl ial risk to the letus. Nonlerafogenle Eli eels. Oose-r elateddecreases in pupVleighl gain and survival Vl ere observedin rals exposed 10anoral dose01150mglkg 01lertenadin e (approximatel v 3 times Ihemaximum reeommendeddaily oraldose 01lexolenadine hydroehloridein adulls basedoneomparison 01lexolenadine hvdroehloride AUCs).
Nursing Mothers
Thereareno adequate and well-eontrolled studiesin women during laetation. Beeause many drugs areexereted in human milk, caution should be exercised when fexofenadine hydrochleride is admi nistered to a nursing woman.
Pediatrie Use
The reeommended doseIn patient s 6 10 11vears 01 age is based on eross-sludy eomparisonof Ihepharmaeokinelies 01 ALLEGRA in adults andpedi alrie pat ientsand onIhe salely profile 01 fexolenadinehydroehloride in bolhadultand pediatrie palient s al doses equal 10 or higherthan Ihe reeommendeddoses. Thesalely 01 ALLEGRA tablels al a dose01 30 mgtwice dail y has been demonstratedin 438pedialrie pat ients 6 to 11years 01agein twoplaeebo-eonlrolled2-week seasonal all ergie rhinitisIrials. Thesafely 01 ALLEGRA lor theIreatment of ehronieidiopathieurtiearia in pati enl s 6 to 11years 01 ageis based oneross-studv eomparison 01 thepharmaeokineties 01 ALLEGRA in adult and pediatriepatients and on Ihesafely profileof lexolenadine in bolh adult and pediatrie pal ienls al doses equal to or higherthanthe reeommendeddose. Theelieetiveness 01 ALLEGRAforthetreatmenl 01 seasonal allergierhini lis in patients 6 to 11years 01age Vl as demonstraled in one trial (n=411) in whieh ALLEGRA tablets 30 mg twice daily signilieanll y redueed total symptom seor es eompared to plaeebo, along Vlith ext rapolation 01 demonstraled eHieaey in pal ients ages 12yearsand above, and thepharmaeokinetiecomparisonsin adults and ehildren. Theelieeliveness 01 ALLEGRA lor the treatment 01ehronie idiopathi e urtiearia in palients 6 10 11 years 01 age is based onan extrapolationof Ihe demonstratedeHieaey 01 ALLEGRA in adults Vl ith Ihis eondilion and the iikel ihood IhalIhediseaseeourse, palhophvsiology and Ihedrug' s elieet are substanlially similar in ehi ldren10Ihal of adultpatienl s. The salely and eHeeliveness 01ALLEGRA in pediatriepal ients under 6 years 01age havenoi beenestablished.
Geriatrie Use
Clinieal sludies 01ALLEGRA tablets andeapsules did not inelude suHiei entnumbers 01 subjeets aged 65years and over 10 determine Vl het her Ihis population responds dilierentlv from younger patients. Other reported cli nical expe rience has net identified differences in responses betweenthe geriatr icandyounger patients. This drug is knovln 10 be substantiallv exereled by Ihekidney, and Ihe risk 01 toxie reaetions 10 Ihis drug may be greaterin patientswith impairedrenalfunction. Becauseelderlypatientsaremere Iikel ytohavedecreased renal 6riel Summary 01 Preseribing Inlormalion as01February 2000 ALLEGRA® (Iexolenadine hydrochloride)
Capsules and Tablets
INDlCATIONS ANO USAGE Seasonal AII" . leRhinilis ALLEGRA is indi ealed tor thereliel 01symplomsassociat edwith seasonal allergierhinilis in adul ts andehildren 6 years 01 age and older. Symptoms Irealed eHeetively were sneezing. rhinorrhea, itehy nose/palate/throal, itehy/wat ery/red eyes. Chronle Idiopalhie Urt learia ALLEGRA is indieated lor treatment 01 uneomplieatedskin manifestations 01chronic idiopathie urtieari a in adults and ehi ldren 6 years 01 age andolder. II signi l ieantly reduees pruritus and thenumber 01 wheals. CONTRAINOICATlONS ALLEGRA is eonl raindieatedin patlents wilh known hypersensilivily 10any01its ingredients.
PRECAUTIONS OruQ Interactlonwith Ervthromycin and Ketocona zol e
Fexolenadine hydroehloride nas been shown to exhibit minimal (ca. 
. Preop erati ve ax ial CT ima ges. A: Lat erally retra cted medial maxillary sinus wall (an·ow). B: A telec tatic left max illa ry sinus with a seg tnental bOIl Y dehi scence of the poste rolatera l sinus wa ll (a rrow) and all intralu minal ret raction of the posterior sinus wall p eriosteum (arrowhead) , Note the increas ed width of the fat plane p osterior to the left max illary siili/S.
A
Figu re 1. Preop erat ive coronal CT irnages. A: Left max illary sinus atelectasis, with a lat erally retrac ted uncinat e p rocess devoid of bone and dir ectly opposing the lamina papyracea (a rrow) and a dep ressed left orbita l floo r devo id ofbone medially (arrowhead). B: Vest igial left middle turbinate retracted laterally, ca using frontal recess obstruc tion (arrow).
A sor for the de velopment of ac ute A and chronic sinusitis. Additionally, alterations in ventilation ca n result in bone rem odel ing or destruction as aresult ofpressure effects. For instance, an aerocele ca uses sinus exp ans ion because of one-way air-trapping,I whereas atelectas is reduces sinus volume bec ause of a complete ostial obstruc tio n, with a sub sequent gas resorption and formation of a vacuum. Dr awin g an analogy to eustachian tube dy sfunction in the development of negative middle ear pre ssure, Sch arf et al used rabb its to ex perimentally prove a causal rel ation ship between ostial occlusion and the development ofsubatmospheric pressure in the maxillary sinus.' Kass et al manometrically ver ified this finding in humans who had reduced maxillary sinus volume as noted by eT.3
Enophthalmos result ing from maxill ary sinus pathology wa s first repo rted by Mont gom ery in 1964. 4 In the two ca ses he reported, asy mptomatic muc ocele s wer e the cause of orbital floor destruction, which resulted in a prol apse of the orbital contents, with associated ocular findings only. Over the ensuing 35 yea rs, num erou s cas e studies and reviews have shed further light on the patho genesis and man agement of thi s and similar conditions. Chronic maxilla ry atele ctasis is a descriptive term to desc rib e a long-st anding diminution of maxillary sinus volume and radio graphic finding s of an inward bo win g ofthe walls of the antrum.' As one man 's ceiling is the next man' s floor, an inerease in orbital volume would be expected as the antral roof sags . Although chronic maxillary atelectasis doe s not neces-Volume 79 , Number 8 HUNT, TA MJ sarily resuIt in enophthalmos, ehanges in orbital volume are common, as the thin superior and posterolateral walls of the maxiIIary sinus are most frequently involved in the remodeling process .' When ehronie obstruetion ofventi-Iation to the maxiIIary sinus affliets the developing faeial strueture of achiid, a hypoplastie sinus asyrnrnetry-? and possibly vertieal dystopia of the eye ean result. 8 Differen- tiation from a Parry -Romberg syndrome ean be diffieult in this setting.? Radiologie studies have shown that max-iIIary sinus hypoplasia is found in I to 17.5% of radiographs taken for the evaluation of ehronie sinusitis. s-"'"
The eharaeteristie C'I' findings in patients with hypoplastie or ateleetatie maxiIIary sinus incIude osteomeatal eomplex obstruetion, a C-shaped lateral bowing of the uneinate process, sinus opaeifieation, and internai bowing of the posterolateral, superior, and media l walls of the sinus . Additio nally, anterior wall bowing, a widen ing of the pterygopalatine fossa and infratemporal fossa fat plane, an eleva tion of the canine fossa , or a relative ly lateral position of the infraorbital eana l might be seen. 12 • 13 Whe ther the maxiIIary sinus walls simp ly remodel or attenuate seems to relate to the duration of the pathologie process . A trend that we noted upon review ing the literature was that patient reeogni tion of progressive enoph - thalmos over a period of 3 months or less corresponded with an attenuation or absence of the involved bony sinus walls , whereas a more insidious deve lopment of this change corresponded with bony remodeling. Symptoms resulting from prolonged hypoventilation of the maxi llary sinus are sometimes absent. When they do manifest, they can incl ude a constellation of pressure, pain, and obstruetion similar to that seen in ehronie sinusitis. The presenee or absenee of symptoms ean be determined by the degree and duration of negative pressure, the presenee of inflammation, or the degree of previous pneumatization. Patients who have few or no symptoms have been observed to demonstrate more signifieant bony ehanges than their more symp tomatie eounterparts .'
Our patient's eondition fits the deseription of ehronie maxi llary ateleetasis as proposed by Kass et al. 3 The asymptomatie nature of his maxillary sinus pathology allowed for the development of eosmetieally signifieant enophthalmos prior to diagnosis. More speeifieally, beeause he had no known history of trauma or inflammatory disease of the paranasal sinuses, our patient's eondition more closely fits the features of the silent sinus syndrome proposed by Soparkar et al in 1994 (table 1) .14 In the only other referenee to this syndrome to date, Rose deser ibed a ease that was nearly identieal to ours ." In reviewing the reported cases of aequired maxillary sinus hypoplasia and ehronie maxillary ateleetasis (of adequate detail), we found 18 patients who met these more seleetive eriteria (table 2).4.5.9.16.23 Including our ease and that of Rose, the mean age at diagnosis was 42 years , and the male-tofemale ratio was 14-to-6. When noted, the mean duration of eosmetie ehange prior to diagnosis was 8.9 months.
Management of patients with maxillary sinus atelee tasis is prima rily by endoseop ie uneineetomy and maxillary antros tomy to remove the obstrue ting soft tissue and to reestablish an isobarie sinus. We reiterate the eounsel of eaution given by severa l authors rega rding endoseopie surgery on the lateral nasal wall in this setting of altered uneinate process anatorny .v":" Pene tration of the lamina papyraeea might oeeur if a vigilant search for the free margi n of the lateralized uneinate is not undertaken. 
